The exact cancer diagnosis matters. US Wegovy labeling contraindicates use with a personal or family history of medullary thyroid carcinoma or with MEN2. Other thyroid cancers need a separate clinical assessment.
First, identify the cancer type
Wegovy contains semaglutide, a GLP-1 receptor agonist. US labeling contraindicates it with a personal or family history of medullary thyroid carcinoma (MTC), or if the patient has multiple endocrine neoplasia type 2 (MEN2). Papillary or follicular cancer in a relative is not automatically covered by that MTC contraindication, but does not establish that treatment is appropriate for you.[1]
Why medullary thyroid cancer is different
MTC arises from calcitonin-producing C cells; papillary and follicular cancers arise from follicular cells. Some MTC is hereditary and associated with MEN2 and pathogenic germline RET variants. Normal thyroid function tests, such as TSH, do not rule out MTC.[2] A MEN2 family history or a known pathogenic germline RET variant calls for specialist assessment.[7]
US and Korean labeling differ
The US warning began with C-cell tumors in rodents; relevance to humans remains uncertain.[1] The Korean Wegovy 2.4 product information checked on October 2, 2026 did not list the same MTC/MEN2 contraindication. Its nonclinical information describes rodent tumors and says human risk cannot be completely excluded.[3] This difference is not proof of safety in high-risk families. Check your own product's current local labeling and consult an endocrinologist.[7]
What human studies show
Studies are mixed. Most concern people with type 2 diabetes and several GLP-1 medicines, rather than Wegovy alone for obesity. Observational associations cannot prove causation; short follow-up and rare MTC events limit conclusions.[4][5][6][8]
HR is relative to the comparator, not the probability of getting cancer. A 95% confidence interval containing 1 does not establish zero risk. These average results do not establish safety in MTC/MEN2 families; some Nordic data overlap between the 2024 and 2025 studies.[5][6]
| Study | Population and follow-up | Finding and limitation |
|---|---|---|
| France · 2023 [4] | Type 2 diabetes; 1–3 years of cumulative use | All thyroid cancers: HR 1.58 (95% CI 1.27–1.95); MTC: 1.78 (1.04–3.05). Observational association. |
| Nordic countries · 2024 [5] | 145,410 GLP-1 users; mean follow-up 3.9 years | HR 0.93 (0.66–1.31) versus DPP-4 inhibitors. No clear increase; MTC estimate imprecise. |
| International · 2025 [6] | 98,147 GLP-1 users; includes South Korea; median follow-up 1.8–3.0 years | HR 0.81 (0.59–1.12) versus DPP-4 inhibitors. Long-term and MTC-specific risk unresolved. |
| US · 2025 [8] | Type 2 diabetes; 41,112 GLP-1 initiators | Overall HR 1.24 (0.88–1.76); first year 1.85 (1.11–3.08). Greater early detection is one possible explanation. |
Prepare these details for your prescriber
If MTC family history becomes known during treatment, contact your prescriber before the next dose. For MEN2 or hereditary MTC in the family, discuss specialist evaluation and whether genetic counseling or testing is needed.[2][7]
- Affected relative and age at diagnosis.
- Exact cancer type in the pathology report.
- MEN2 diagnosis or pathogenic germline RET variant in the family.
- Your own cancer, nodule and treatment history; medication name and dose.
Does a normal test make treatment safe?
US labeling describes the value of routine calcitonin testing or thyroid ultrasound as uncertain. The 2026 UK society statement does not recommend screening all unselected patients.[1][7] A normal test does not remove an MTC family-history contraindication. A neck lump, persistent hoarseness or swallowing difficulty needs assessment; breathing difficulty needs emergency care.[1]
A small check-in today
- Have you confirmed the relative's exact diagnosis?
- Have you told your prescriber about MTC, MEN2 or RET findings?
- Have you checked your product's local labeling?
Frequently asked questions
What if the family only remembers 'thyroid cancer'?
Request the diagnosis or pathology report. Tell your prescriber that the type is unknown; do not assume it was papillary cancer.
Do the same restrictions apply to every GLP-1 medicine?
Check each product and country separately. This article centers on Wegovy; labeling is not identical for every GLP-1 medicine or GIP/GLP-1 dual agonist.
The GLP1 Helper editorial team prepared this general information from public sources. It has not received individual medical-expert review. It does not replace diagnosis or prescribing. Confirm approved uses and instructions in your country with your prescriber or pharmacist. Editorial principles
References
- DailyMed · Wegovy US prescribing informationUS approved labeling · Source checked 2026-10-02
- American Thyroid Association · Medullary thyroid cancerProfessional society patient information · Source checked 2026-10-02
- MFDS · Korean Wegovy 2.4 product informationKorean approved product information · Source checked 2026-10-02
- Bezin et al. · France, Diabetes Care, 2023Observational research · Source checked 2026-10-02
- Pasternak et al. · Nordic cohort, BMJ, 2024Observational research · Source checked 2026-10-02
- Baxter et al. · International cohort, Thyroid, 2025Observational research · Source checked 2026-10-02
- SfE / BTA / BAETS · UK joint statement, 2026Professional society guidance · Source checked 2026-10-02
- Brito et al. · US cohort, JAMA Otolaryngology, 2025Observational research · Source checked 2026-10-02